Pharmaceutical & Biotechnology Companies: The segment held the largest market share, approximately 45%, in 2024, due to high R&D expenditures to develop new drug formulations, therapies and vaccines. Both sectors depend on extensive quality control and advanced manufacturing for drugs and biologics that require a wide array of consumables, such as cell culture vessels and filtration devices. Pharmaceutical and biotech companies rely heavily on pipette tips, media, buffers, chromatography cartridges and microplates for routine assays, stability studies and high-throughput screening. Growing investments in biologics, including monoclonal antibodies, gene therapies and mRNA platforms, further increase demand for sterile, high-precision consumables used throughout upstream and downstream processing.
Clinical & Diagnostic Labs: The segment is expected to witness the fastest CAGR during the foreseeable period of 2025-2034. The segment is growing due to greater public and private investments in healthcare infrastructure, particularly in emerging economies, which help expand research capacity and diagnostic facilities. Also, technologies such as NSG, molecular diagnostics, and point-of-care testing offer highly accessible, precise diagnostics, driving demand for associated consumables.
Academic & Research Institutes: The segment is notably growing due to rising investments in R&D, rising rates of complex diseases and chronic conditions and the expansion of new research sectors such as genomics and personalized medicines. The increasing number of chronic and infectious diseases is a key driver of the segments growth. Universities, national laboratories and medical research centers are increasingly adopting advanced consumables for cell biology, molecular diagnostics, sequencing and proteomics to support large-scale research projects.
Contract Research Organizations (CROs): The segment is expanding due to the rising rate of outsourcing R&D and clinical trials, the growing focus on new therapeutic areas to develop personalized medicine, biologics and cancer treatment solutions and the resulting demand for CROs. CROs increasingly manage complex workflows such as biomarker analysis, high-throughput screening, genomic profiling and immunology assays, all of which require large volumes of specialized consumables. Pharmaceutical and biotech companies rely heavily on CROs to accelerate study timelines, reduce operational costs and access advanced laboratory capabilities without building in-house facilities.